[go: up one dir, main page]

CL2016000466A1 - Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer. - Google Patents

Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer.

Info

Publication number
CL2016000466A1
CL2016000466A1 CL2016000466A CL2016000466A CL2016000466A1 CL 2016000466 A1 CL2016000466 A1 CL 2016000466A1 CL 2016000466 A CL2016000466 A CL 2016000466A CL 2016000466 A CL2016000466 A CL 2016000466A CL 2016000466 A1 CL2016000466 A1 CL 2016000466A1
Authority
CL
Chile
Prior art keywords
bmi
cancer
substituted
compounds derived
inhibitors
Prior art date
Application number
CL2016000466A
Other languages
English (en)
Inventor
Ramil Baiazitov
Wu Du
Young-Choon Moon
Steven D Paget
Hongyu Ren
Nadiya Sydorenko
Richard Gerald Wilde
Chang-Sun Lee
Original Assignee
Ptc Theraputics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Theraputics Inc filed Critical Ptc Theraputics Inc
Publication of CL2016000466A1 publication Critical patent/CL2016000466A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DERIVADOS DE 2-AMINO PIRIDIMIDINA SUSTITUIDA, SUS SALES, HIDRATOS, SOLVATOS, QUELATOS, CLATRATO, POLIMORFO, ISOTOPÓLOGO, ESTEREOISÓMERO, RACEMATO, ENANTIÓMERO, DIASTEREÓMERO O TAUTÓMERO DE LOS MISMOS, QUE INHIBEN LA FUNCIÓN DE LA PROTEÍNA DEL SITIO DE INTEGRACIÓN 1 DEL VIRUS DE LA LEUCEMIA MURINA DE MOLONEY ESPECIFICO DE LOS LINFOCITOS B BMI-1 Y QUE REDUCEN EL NIVEL DE LA MISMA Y USO DE LOS COMPUESTOS PARA INHIBIR LA FUNCIÓN DE BMI-1 PARA TRATAR UN CÁNCER MEDIADO POR LA BMI-1
CL2016000466A 2013-08-30 2016-02-29 Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer. CL2016000466A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361872091P 2013-08-30 2013-08-30
PCT/US2013/071216 WO2015030847A1 (en) 2013-08-30 2013-11-21 Substituted pyrimidine bmi-1 inhibitors

Publications (1)

Publication Number Publication Date
CL2016000466A1 true CL2016000466A1 (es) 2016-10-21

Family

ID=52587180

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000466A CL2016000466A1 (es) 2013-08-30 2016-02-29 Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer.

Country Status (16)

Country Link
US (1) US10370371B2 (es)
EP (1) EP3039015B1 (es)
JP (2) JP6524094B2 (es)
KR (1) KR102232595B1 (es)
CN (1) CN105683166B (es)
AR (1) AR093580A1 (es)
AU (2) AU2013399092A1 (es)
CA (1) CA2922657C (es)
CL (1) CL2016000466A1 (es)
EA (1) EA034866B1 (es)
IL (1) IL244321B (es)
MX (1) MX370588B (es)
NZ (2) NZ718055A (es)
TW (1) TWI692477B (es)
WO (1) WO2015030847A1 (es)
ZA (1) ZA201601697B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922657C (en) * 2013-08-30 2022-04-12 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
CA3012031C (en) 2016-01-22 2024-03-26 Janssen Pharmaceutica Nv 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
US11180487B2 (en) 2016-01-22 2021-11-23 Janssen Pharmaceutica Nv Substituted cyanoindoline derivatives as NIK inhibitors
SG11201809751XA (en) 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds
JP6936815B2 (ja) 2016-06-30 2021-09-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
AU2018352695A1 (en) 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
GEP20227433B (en) 2018-04-26 2022-10-25 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
CN112533581B (zh) 2018-06-07 2024-08-30 密歇根大学董事会 Prc1抑制剂及用其进行治疗的方法
BR112021002630A2 (pt) 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
BR112021016747A2 (pt) * 2019-02-28 2021-10-19 Ptc Therapeutics, Inc. Método para tratamento de um meloma múltiplo
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
TW202521536A (zh) 2019-05-05 2025-06-01 美商基尼特奇公司 Ｃｄｋ抑制劑
WO2021003517A1 (en) * 2019-07-10 2021-01-14 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[l,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin- 2-amine as therapeutic agents
EP4003992A1 (en) * 2019-07-24 2022-06-01 Merck Patent GmbH 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives
PH12022550361A1 (en) 2019-08-14 2023-02-27 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
WO2023250439A1 (en) * 2022-06-22 2023-12-28 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof
WO2025024388A1 (en) 2023-07-21 2025-01-30 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (es) 1973-09-20 1977-11-30 Delalande Sa
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0607332B1 (en) 1991-10-07 1997-12-17 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction
JP2896532B2 (ja) * 1994-08-13 1999-05-31 ユーハン コーポレーション 新規なピリミジン誘導体およびその製造方法
IN188411B (es) * 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) * 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
EP1206265B1 (en) * 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ES2306671T3 (es) 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
EP1224185B1 (en) 1999-10-27 2005-11-30 Novartis AG Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
JP5074653B2 (ja) * 2000-03-29 2012-11-14 サイクラセル リミテッド ２−置換４−ヘテロアリール−ピリミジンおよび増殖性障害におけるその使用
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
PT1330452E (pt) 2000-09-20 2009-01-22 Ortho Mcneil Pharm Inc Derivados de pirazina como moduladores de tirosina-cinases
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ATE416175T1 (de) * 2001-02-20 2008-12-15 Astrazeneca Ab 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
CA2439263C (en) 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
DE60214198T2 (de) * 2001-07-03 2007-08-09 Vertex Pharmaceuticals Inc., Cambridge Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
RU2315043C2 (ru) 2002-06-28 2008-01-20 Ниппон Синяку Ко., Лтд. Амидное производное, фармацевтическая композиция и терапевтические средства на его основе
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
JP2006504755A (ja) * 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
GB2432834A (en) 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
US20070117818A1 (en) * 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
AU2006219231B2 (en) 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
CA2601257A1 (en) 2005-03-10 2006-09-21 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
DE602007004618D1 (de) 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
CN101516873A (zh) 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
MX2009003142A (es) 2006-10-03 2009-04-06 Neurosearch As Derivados de indazolilo utiles como agentes moduladores del canal de potasio.
ES2383370T3 (es) 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
WO2008079933A2 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
UY31048A1 (es) 2007-04-25 2008-11-28 Astrazeneca Ab Nuevos compuestos de pirimidina y usos de los mismos
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
CN101910152B (zh) 2007-11-16 2014-08-06 因塞特公司 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
KR20100098521A (ko) * 2007-12-07 2010-09-07 노파르티스 아게 피라졸 유도체 및 그의 사이클린 의존성 키나제 억제제로서의 용도
DE102008005493A1 (de) * 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) * 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010002985A1 (en) 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
EP2331527A1 (en) 2008-09-02 2011-06-15 NeuroSearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
WO2010092962A1 (ja) 2009-02-12 2010-08-19 アステラス製薬株式会社 へテロ環誘導体
JP5766177B2 (ja) 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
TW201102387A (en) 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP2012533553A (ja) * 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピリジン系キナーゼ阻害薬
JP5415176B2 (ja) 2009-08-06 2014-02-12 株式会社マキタ スイッチ
AU2011206621B2 (en) 2010-01-12 2016-04-14 Ab Science Thiazole and oxazole kinase inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
CN103025725B (zh) 2010-08-10 2015-09-16 安斯泰来制药有限公司 杂环化合物
RS54544B1 (sr) 2010-09-13 2016-06-30 Novartis Ag Triazin-oksadiazoli
US20140088056A1 (en) 2010-09-28 2014-03-27 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
AU2011338389A1 (en) 2010-12-09 2013-06-13 Amgen Inc. Bicyclic compounds as Pim inhibitors
US9890138B2 (en) 2011-02-25 2018-02-13 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
WO2013004332A1 (en) 2011-07-07 2013-01-10 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR20220143164A (ko) 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
CA2922657C (en) * 2013-08-30 2022-04-12 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors

Also Published As

Publication number Publication date
MX2016002642A (es) 2016-08-12
HK1226057A1 (zh) 2017-09-22
JP2016529292A (ja) 2016-09-23
CA2922657C (en) 2022-04-12
JP6524094B2 (ja) 2019-06-05
EP3039015A1 (en) 2016-07-06
EA034866B1 (ru) 2020-03-31
EP3039015A4 (en) 2017-01-11
CN105683166B (zh) 2020-06-16
JP2019059778A (ja) 2019-04-18
JP6728321B2 (ja) 2020-07-22
CA2922657A1 (en) 2015-03-05
KR20160048920A (ko) 2016-05-04
EP3039015B1 (en) 2019-10-30
AU2013399092A1 (en) 2016-03-17
EA201690502A1 (ru) 2016-08-31
CN105683166A (zh) 2016-06-15
AU2018271277A1 (en) 2018-12-20
ZA201601697B (en) 2021-07-28
AU2018271277B2 (en) 2020-07-16
US10370371B2 (en) 2019-08-06
IL244321B (en) 2020-07-30
NZ718055A (en) 2020-01-31
MX370588B (es) 2019-12-16
TW201512188A (zh) 2015-04-01
IL244321A0 (en) 2016-04-21
TWI692477B (zh) 2020-05-01
NZ748260A (en) 2020-01-31
KR102232595B1 (ko) 2021-03-26
US20160214978A1 (en) 2016-07-28
AR093580A1 (es) 2015-06-10
WO2015030847A1 (en) 2015-03-05
BR112016004511A8 (pt) 2021-11-30
BR112016004511A2 (pt) 2017-09-12

Similar Documents

Publication Publication Date Title
CL2016000466A1 (es) Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer.
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
MX2016013182A (es) Tratamiento de neoplasias malignas de linfocitos b mediante una combinacion de inhibidores de janus cinasa (jak) y fosfatidilinositol 3 cinasa (pi3k).
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX389825B (es) Compuestos y composiciones para tratar trastornos hematologicos.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
AR103680A1 (es) Inhibidores selectivos de bace1
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.